From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

The number of HIV diagnoses in the Netherlands is no longer falling and infections are on the rise among young men, according ...

The Dutch Aids foundation Aidsfonds says it is concerned about the rise in cases of HIV in young men who have sex with men.

Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment ...

On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...